Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (Toomey et al), conducted under the direction of Dr. Bryan Hennessy of the Beaumont Hospital in Dublin, Ireland, supports the findings that RDA is an effective prediction tool for which patients will have a higher likelihood of achieving a pathological complete response (pCR) in response to chemotherapy and targeted therapy.
For the full press release, click here
For the Journal Article, click here